Yaping Chen

Hangzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications

Surveillance and analysis of adverse events following immunization (AEFI) with measles, mumps, and rubella (MMR) vaccine in Zhejiang Province, China, 2020-2025.

Surveillance and analysis of adverse events following immunization (AEFI) with measles, mumps, and rubella (MMR) vaccine in Zhejiang Province, China, 2020-2025.

Journal: Frontiers in public health
Published: April 02, 2026

Immunogenicity and safety of co-administered Escherichia coli-produced bivalent HPV-16/18 vaccine and hepatitis E vaccine.

Immunogenicity and safety of co-administered Escherichia coli-produced bivalent HPV-16/18 vaccine and hepatitis E vaccine.

Journal: Frontiers in immunology
Published: March 24, 2026

Factors associated with serious adverse event following immunization: a real-world analysis of the vaccine adverse event reporting system 2025.

Factors associated with serious adverse event following immunization: a real-world analysis of the vaccine adverse event reporting system 2025.

Journal: Frontiers in public health
Published: March 02, 2026

Adverse Events Following Haemophilus influenzae Type b (Hib) Monovalent Vaccines in Zhejiang Province, China, from 2017 to 2023.

Adverse Events Following Haemophilus influenzae Type b (Hib) Monovalent Vaccines in Zhejiang Province, China, from 2017 to 2023.

Journal: Vaccines
Published: February 11, 2025

Surveillance of Adverse Events Following Varicella Vaccine Immunization in Zhejiang Province, China, from 2020 to 2022.

Surveillance of Adverse Events Following Varicella Vaccine Immunization in Zhejiang Province, China, from 2020 to 2022.

Journal: Vaccines
Published: December 06, 2024

Surveillance of psychogenic adverse events following immunization in Zhejiang, China, 2020-2023.

Surveillance of psychogenic adverse events following immunization in Zhejiang, China, 2020-2023.

Journal: BMC public health
Published: October 09, 2024

A Serological Survey of Measles and Rubella Antibodies among Different Age Groups in Eastern China.

A Serological Survey of Measles and Rubella Antibodies among Different Age Groups in Eastern China.

Journal: Vaccines
Published: May 30, 2024

Non-linear effects of age in reporting of adverse events following influenza immunization in Zhejiang, China.

Non-linear effects of age in reporting of adverse events following influenza immunization in Zhejiang, China.

Journal: BMC infectious diseases
Published: December 18, 2023

Cost-effectiveness analysis of introducing rotavirus vaccine into immunization program in Zhejiang province, China: A decision tree-Markov model study.

Cost-effectiveness analysis of introducing rotavirus vaccine into immunization program in Zhejiang province, China: A decision tree-Markov model study.

Journal: Human vaccines & immunotherapeutics
Published: July 17, 2023

Safety and Immunogenicity of Enterovirus 71 Vaccine (Vero Cell) Administered Simultaneously with Trivalent Split-Virion Influenza Vaccine in Infants Aged 6-7 Months: A Phase 4, Randomized, Controlled Trial.

Safety and Immunogenicity of Enterovirus 71 Vaccine (Vero Cell) Administered Simultaneously with Trivalent Split-Virion Influenza Vaccine in Infants Aged 6-7 Months: A Phase 4, Randomized, Controlled Trial.

Journal: Vaccines
Published: February 28, 2023

Real-world safety profile of the 9-valent human papillomavirus vaccine: A study in Zhejiang, China from 2019 to 2021.

Real-world safety profile of the 9-valent human papillomavirus vaccine: A study in Zhejiang, China from 2019 to 2021.

Journal: Human vaccines & immunotherapeutics
Published: December 09, 2022

Immunogenicity and safety of an inactivated enterovirus 71 vaccine coadministered with trivalent split-virion inactivated influenza vaccine: A phase 4, multicenter, randomized, controlled trial in China.

Immunogenicity and safety of an inactivated enterovirus 71 vaccine coadministered with trivalent split-virion inactivated influenza vaccine: A phase 4, multicenter, randomized, controlled trial in China.

Journal: Frontiers in immunology
Published: October 26, 2022
Showing 1-12 of 55

Last Updated: 09/26/2026